Eric helps clients with antitrust matters, including civil and criminal defense as well as counseling for mergers and acquisitions, settlements of pharmaceutical patent litigation, and strategic planning. Since 2001, he also has helped clients with concerns under the Foreign Corrupt Practices Act (FCPA) and other anti-corruption issues. Eric began at the firm as a summer associate in 1997 and has been a partner since 2007.
For clients with needs outside Eric's areas of specialization, he often serves as a relationship partner, ensuring that the client receives the firm's best work and advice, efficiently and cost-effectively. In that role, Eric also works to ensure that a client's work streams create opportunities for attorneys at White & Case in line with the client company's values.
A former prosecutor, Eric returned to White & Case after serving as Counsel to the Assistant Attorney General in charge of the Antitrust Division of the United States Department of Justice (DOJ) in 2003-04, where he helped formulate US antitrust enforcement policy and manage the civil and criminal investigations and court cases brought by the Antitrust Division. He ended his DOJ service with a detail as a Special Assistant US Attorney in the District of Columbia, trying twenty bench and jury trials as lead counsel.
In private practice, Eric has argued on behalf of clients in district courts across the country, including a successful verdict for defendants in an antitrust jury trial, argued appeals in the Eleventh and DC Circuits, and worked on twelve matters before the US Supreme Court, ten of which were antitrust cases. Other recent successes on behalf of clients include defeating class certification for direct purchasers, obtaining the dismissal of indirect-purchaser actions, winning summary judgment, and successfully moving to bifurcate a trial into two phases, all in different pharmaceutical antitrust cases.
Eric clerked for the Honorable Walter K. Stapleton, US Court of Appeals for the Third Circuit, 1999-2000, and the Honorable Federico A. Moreno, US District Court for the Southern District of Florida, 1998-99.
He is a member of the Legal Policy Board of the Washington Legal Foundation.
Eric serves on the Executive Committee of the Corporations, Securities, and Antitrust Practice Group of the Federalist Society.
He served a three-year term, 2015-18, on the American Bar Association's Standing Committee on Amicus Curiae Briefs.
He previously served as Vice-Chair of the Health Care and Pharmaceuticals Committee of the American Bar Association Section of Antitrust Law, and prior to that as Vice-Chair of its Compliance and Ethics Committee.
Eric has served as an adjunct faculty member at the Howard University School of Law, where he taught a seminar on advanced antitrust law.
Eric's results for clients have been recognized in Chambers, Legal 500, LMG Life Sciences, the Global Competition Review, Competition Law360, Euromoney's Guide to the World's Leading Competition and Antitrust Lawyers/Economists, the American Lawyer, Who's Who Legal: Competition, U.S. News & World Report, Best Lawyers in America, and Super Lawyers.
In re Namenda Direct Purchaser Antitrust Litigation: Successfully moved pursuant to Rule 42(b) of the Federal Rules of Civil Procedure to bifurcate trial into two phases, enabling the jury to separately consider plaintiffs' reverse payment and product-hopping claims (S.D.N.Y. June 4, 2019).
In re Zetia (Ezetimibe) Antitrust Litigation: Eric served as lead counsel for a pharmaceutical company defending against class-action antitrust claims. His role in this matter included:
- (i) Obtaining the voluntary dismissal of all of the complaints against his client, prior to any discovery and with no settlement payment (September 28, 2018); and
- (ii) winning a contested motion for centralization under 28 U.S.C. § 1407, before the Judicial Panel on Multidistrict Litigation, to the client's preferred venue in In re Zetia (Ezetimibe) Antitrust Litigation, MDL No. 2836 (J.P.M.L. June 8, 2018).
FTC v. Actavis: Eric served as lead trial counsel for two pharmaceutical companies defending against, formerly, class-action antitrust claims. His role in this matter included:
- (i) Successfully arguing the opposition to direct-purchaser, retailer plaintiffs' motion under Rule 42(a) of the Federal Rules of Civil Procedure to consolidate their claims for trial with those of the FTC; Eric's clients were the only defendants, out of three groups of defendants in the case, to oppose the retailers' motion (2018);
- (ii) successfully opposing direct-purchaser plaintiffs' motion for class certification, which appears to be only the second time that direct purchasers have been denied class certification in a reverse payment case in the approximately twenty years that such cases have been litigated (2018);
- (iii) successfully arguing a Daubert motion to exclude and limit the testimony of plaintiffs' proposed pharmaceutical manufacturing valuation expert (2018);
- (iv) obtaining the voluntary dismissal with prejudice of the FTC's complaint with zero damages, no liability, and no injunctive relief beyond that already agreed to previously by the client’s corporate parent in a separate matter (2017);
- (v) obtaining the voluntary dismissal with prejudice of all indirect-purchaser actions with zero damages, no liability, and no injunctive relief (2016);
- (vi) defeating the FTC and private plaintiffs' motion to compel the production of common-interest privileged communications, establishing an important precedent for protecting the confidentiality of joint-defense antitrust advice for settling patent litigation, In re AndroGel Antitrust Litigation, No. 09-MD-2084, 2015 WL 9581828 (N.D. Ga. Dec. 30, 2015);
- (vii) serving as counsel of record in the US Supreme Court for two respondents opposing the FTC on the merits, and previously opposing the FTC's petition for a writ of certiorari, in FTC v. Actavis, Inc., 133 S. Ct. 2223 (2013) (5-3 decision reversing and remanding FTC v. Watson Pharm., Inc., 677 F.3d 1298 (11th Cir. 2012));
- (viii) successfully arguing a motion for summary judgment against the sham-litigation claims of putative class-action plaintiffs in In re AndroGel Antitrust Litigation, 888 F. Supp. 2d 1336 (N.D. Ga. 2012);
- (ix) successfully arguing in the US Court of Appeals for the Eleventh Circuit against the FTC's appeal in FTC v. Watson Pharm., Inc., 677 F.3d 1298 (11th Cir. 2012);
- (x) successfully arguing a motion to dismiss against the FTC's "pay for delay" lawsuit, In re AndroGel Antitrust Litigation, 687 F. Supp. 2d 1371 (N.D. Ga. 2010);
- (xi) winning a contested motion for centralization under 28 U.S.C. § 1407, before the Judicial Panel on Multidistrict Litigation, to the clients' preferred venue in In re AndroGel Antitrust Litigation, MDL No. 2084 (J.P.M.L. 2009);
- (xii) winning a contested transfer motion under 28 U.S.C. § 1404 to transfer both the government and private antitrust actions to the original patent judge to defeat FTC and private-plaintiff forum shopping, FTC v. Watson Pharm., Inc., 611 F. Supp. 2d 1081 (C.D. Cal. 2009); and
- (xiii) defending clients and their executives in the underlying two-year FTC investigation, including at six investigational hearings.
Counseling Pharmaceutical Patent Settlements: Eric also has counseled more than forty pharmaceutical patent settlements that have avoided challenge by the FTC and class-action bar.
Other Class-action Litigation:
- Counsel for petitioner in Toshiba Corp. v. Automotive Indus. Pension Trust Fund, which challenges the Ninth Circuit's reversal of the district court's dismissal of a class-action suit premised on the extraterritorial application of the US securities laws based on unsponsored American Depositary Receipts (ADRs), Supreme Court docket No. 18-486, cert. denied June 24, 2019; currently serving as trial counsel in the remand litigation.
- Co-lead counsel for petitioners in the defense win in Stolt-Nielsen, S.A. v. AnimalFeeds Int'l Corp., 130 S. Ct. 1758 (2010), which changed US law by making it more difficult for plaintiffs to assert class-action claims in arbitration. This victory won the Litigation Category that year in the Financial Times US Innovative Lawyers Report. Competition Law360 featured this win in naming White & Case one of the top five class-action defense firms in 2010.
- Co-lead counsel for respondents in Mississippi ex rel. Jim Hood v. AU Optronics Corp., 134 S. Ct. 736 (2014), which concerns the removability of state attorney general actions to federal court under the Class Action Fairness Act of 2005 (CAFA).
- Lead counsel for the Chamber of Commerce of the United States of America as amicus curiae in Jock v. Sterling Jewelers Inc., 646 F.3d 113 (2d Cir. 2011), a class-arbitration case turning on the application of Stolt-Nielsen, S.A. v. AnimalFeeds Int'l Corp., 130 S. Ct. 1758 (2010).
- Co-lead author of successful motion to dismiss a predatory pricing case in In re Parcel Tanker Shipping Servs. Antitrust Litig., 541 F. Supp. 2d 487 (D. Conn. 2008), which is one of the first decisions obtaining dismissal under the Supreme Court's decisions in Twombly and Weyerhaeuser.
- Part of the team defending respondents in a putative class-action arbitration involving claims of international price fixing and customer allocation in the shipping industry; co-lead author of successful petition to vacate class-arbitration award in Stolt-Nielsen, S.A. v. AnimalFeeds Int'l Corp., 435 F. Supp. 2d 382 (S.D.N.Y. 2006).
- Co-lead author of brief in opposition to certiorari in the then-leading case on settlement of pharmaceutical patent litigation: FTC v. Schering-Plough Corp. and Upsher-Smith Laboratories, Inc., Supreme Court docket No. 05-273, cert. denied June 26, 2006 (defeating the FTC's certiorari petition and garnering the amicus support of the United States in opposition to the FTC).
- Co-lead counsel successfully defending Malaysian producers of extruded rubber thread against claims of price fixing in Dee-K Enterprises, Inc. v. Heveafil Sdn. Bhd., including: (i) verdict for defendants after a jury trial in federal district court; (ii) unanimous affirmance on appeal to Fourth Circuit, 299 F.3d 281 (4th Cir. 2002); and (iii) lead author of brief in opposition to certiorari, Supreme Court docket No. 02-649, cert. denied June 27, 2003 (garnering the amicus support of the United States). Dee-K v. Heveafil is the leading precedent on the extraterritorial application of the Sherman Act under the "substantial effects" test from the Supreme Court's decision in Hartford Fire Ins. Co. v. California, 509 U.S. 764 (1993).
- Lead counsel successfully resolving a DOJ antitrust grand jury investigation in the Southern District of New York of a US-based multinational company suspected of price-fixing and bid-rigging involving major metropolitan infrastructure projects in New York City; matter was resolved without an indictment, plea agreement, or parallel civil litigation.
- Lead counsel for a Taiwanese semiconductor manufacturer in both the DOJ's static random access memory (SRAM) antitrust grand jury investigation (which concluded in no indictment despite the cooperation of the amnesty applicant) and the parallel class-action litigations.
- Co-lead author of petition for a writ of certiorari in White & Case LLP v. United States, challenging Ninth Circuit's reversal of district court order quashing DOJ grand jury subpoenas that sought all discovery in parallel, follow-on class actions alleging a cartel in thin-film transistor, liquid crystal display panels (TFT-LCD), and lead counsel coordinating support of eight amici curiae for same, Supreme Court docket No. 10-1147, cert. denied June 27, 2011.
- Co-lead counsel defending a non-US executive in the DOJ's cartel investigation of the dynamic random access memory (DRAM) industry. Lead author of successful motion for a bill of particulars forcing the Antitrust Division to supplement its barebones, formulaic indictment with detailed factual allegations. United States v. Kim, No. 06-0692, (N.D. Cal. Mar. 1, 2007).
- Lead author of petition for a writ of certiorari in the Stolt-Nielsen, S.A. v. United States litigation to enforce an antitrust amnesty agreement against the Antitrust Division of the US Department of Justice, and lead counsel coordinating support of nine amici curiae for same, Supreme Court docket No. 06-97, cert. denied Oct. 30, 2006.
- Part of the team successfully defending against former co-conspirators' attempt to reverse the grant of leniency from the European Commission to Stolt-Nielsen, S.A.
- Lead counsel advising a third-party objector to a biopharmaceutical merger (2019)
- Co-lead merger counsel advising an innovator pharmaceutical company in successful FTC Hart-Scott-Rodino (HSR) clearance of the acquisition of another innovator pharmaceutical company (2018)
- Co-author of petition for a writ of certiorari in Anthem, Inc. v. United States et al., Supreme Court docket No. 16-1342 (filed May 5, 2017), seeking review of United States v. Anthem, Inc., No. 17-5024, 2017 U.S. App. LEXIS 7521 (D.C. Cir. Apr. 28, 2017) (Rogers and Millett, JJ., Kavanaugh, J., dissenting), which affirmed an injunction under Section 7 of the Clayton Act of the proposed merger between Anthem, Inc. and Cigna Corporation; petition voluntarily dismissed upon settlement with the DOJ.
- Lead antitrust counsel advising a leading US tobacco company on the formation of a joint venture for the development of intellectual property.
- Lead US antitrust counsel for an innovator pharmaceutical company in a cross-border acquisition and pharmaceutical product development agreement.
- Lead merger counsel obtaining early termination of the HSR waiting period for review of Iron Mountain Inc.'s acquisition of Archives One, Inc.; anticipated and resolved DOJ's market share concerns within two days.
- Lead counsel for regional wireless service provider as third-party witness concerning a multi-billion dollar telecommunications acquisition; worked with DOJ to achieve divestiture of significant asset of target as sought by client.
- Co-lead merger counsel obtaining early termination of the HSR waiting period for the acquisition of Kos Pharmaceuticals, Inc. by Abbott Laboratories.
- Part of the team litigating the first merger efficiencies defense under the then newly revised horizontal merger guidelines in FTC v. Staples, Inc., 970 F. Supp. 1066 (D.D.C. 1997).
Antitrust Litigation against the Government: In addition to his wins against the FTC in AndroGel, Eric's experience includes several other headline victories against the federal antitrust agencies, including:
- US v. Stolt-Nielsen, 524 F. Supp. 2d 609 (E.D. Pa. 2007) (successfully enforcing amnesty agreement against DOJ's attempted revocation);
- FTC v. Schering-Plough, 402 F.3d 1056 (11th Cir. 2005) (defeating FTC's first "pay for delay" suit); and
- US v. Sungard Data Systems, 172 F. Supp. 2d 172 (D.D.C. 2001) (defeating DOJ's merger challenge).
Foreign Corrupt Practices Act (FCPA):
- Lead counsel managing a post-acquisition, anti-corruption review and audit pursuant to guidance under the DOJ's Corporate Enforcement Program for a multi-national information technology company that had acquired a multi-national software solutions company; leveraged the company's internal audit resources to conduct a cost-effective, risk-based assessment of the acquiree's operations and third-party relationships in six countries.
- Lead counsel advising a multi-national, direct-selling company on its anti-corruption compliance policy and training program for its operations throughout China and Malaysia.
- Lead counsel advising a Fortune 200 company on the due diligence, contractual, and operational compliance issues implicated in the creation of a long-term contract manufacturing relationship with a partner in China.
- Lead counsel representing a UK consulting firm on pre-acquisition due diligence and transaction structuring for an acquisition in Moscow, Russia; led interviews of target's personnel and on-the-ground investigation for same.
- Lead counsel advising board of directors of a Canadian company on FCPA consequences of listing on a US stock exchange; revised corporate compliance program as a result of the US listing.
- Lead counsel representing a Fortune 10 company by handling the FCPA and other compliance negotiations for the company's formation of a joint-venture, real-estate investment vehicle with the investment arm of a leading Middle Eastern government; designed compliance program and employee manual for the j.v. entity.
- Lead counsel representing a Fortune 100 company by conducting the due-diligence investigation and negotiations concerning the FCPA and Mexican-law implications of a proposed acquisition; handled the client's self-report to US enforcement authorities.
- Representing a Fortune 100 company by running more than a dozen compliance investigations on four continents for issues under the FCPA, and managing the investigation self-reports to US enforcement authorities; drafted compliance policies and procedures following conglomerate-wide risk assessment.
- Designing a corporate compliance manual for a multinational construction company for non-US anti-bribery laws enacted pursuant to the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions.
Foreign Sovereign Immunities Act (FSIA):
- Co-lead counsel defending various foreign sovereigns and their agencies and instrumentalities in motion and appellate practice in four different litigations under the FSIA and act-of-state doctrine.
- Lead author of petition for a writ of certiorari in one of the main precedents on attachment and execution under the FSIA: Ministry of Finance of the Republic of Indonesia v. Karaha Bodas Co., Supreme Court docket No. 05-1571, cert. denied Oct. 2, 2006.
General Representation: Eric serves as outside general counsel to the leading corporate advocacy association in the United States.
"The House Judiciary Report—Implications Beyond Big Tech", October 29, 2020: University of Florida Levin College of Law, the University of Florida Competition Policy Initiative, and the George Washington Law School Competition Law Center (panelist)
"The Impact of COVID-19 on the Pharma Industry and Recent Developments Involving Biosimilars", October 21, 2020: Canadian Bar Association Competition Law Fall Symposium (panelist)
"What's Coming Next? Understanding the Next Big Areas in the Pharmaceutical Antitrust Wars", August 24, 2020: Our Curious Amalgam podcast sponsored by the Antitrust Section of the American Bar Association (interviewee)
"The Antitrust 'Failing Firm' Defense in the Wake of the COVID-19 Crisis", June 10, 2020: Federalist Society Corporations, Antitrust & Securities Practice Group Teleforum (moderator)
"Reinvigorating Antitrust: Is Greater Transparency the Answer?", November 15, 2018: Federalist Society National Lawyers Convention: Good Government through Agency Accountability and Regulatory Transparency, (panellist)
"2018 West Coast White Collar Conference: Criminal Antitrust", June 21, 2018: sponsored by the National Association of Criminal Defense Lawyers, (moderator/panelist)
"Institutional Shareholdings: Is There Really an Antitrust Issue?", June 1, 2018: Global Antitrust Economics Conference at New York University's Stern School of Business sponsored by Concurrences, (panelist). There is a video summary of Eric's presentation on the adverse implications of proposals to limit institutional investors to 1% ownership of industry participants due to alleged common ownership antitrust concerns.
"Trump Antitrust Policy After One Year: The United States Department of Justice", January 23, 2018: sponsored by the Heritage Foundation, (panelist)
"Antitrust and Intellectual Property", October 18, 2017: American Bar Association's Antitrust Judicial Law and Economics Institute for Judges at the University of Chicago Law School, (moderator)
"The US Supreme Court: October Term 2017 Preview", September 28, 2017: a media briefing hosted by the Washington Legal Foundation, (moderator)
"Small Wagers, Big Results: How the Supreme Court's Tyson Foods Decision Could Affect Your Practice", October 20, 2016: at the 20th Annual National Institute on Class Actions of the American Bar Association, (panelist)
"Counseling the Alleged Monopolist: Recent Developments", May 17, 2016: sponsored by the Unilateral Conduct Committee of the American Bar Association Section of Antitrust Law, (panelist)
"Freeing Off-Label Use Information: Three Lingering Questions for Medical-Product Innovators & Regulators", May 2, 2016: Washington Legal Foundation media briefing panel, (moderator)
"Leniency Programs and Cooperation Post-Financial Crisis", April 7, 2016: at the 64th Annual Antitrust Law Spring Meeting of the American Bar Association, (moderator)
"How to Settle a Patent Case After Actavis", April 16, 2015: at the 63rd Annual Antitrust Law Spring Meeting of the American Bar Association, (presenter)
"Hot Topics in the Appellate Courts", November 6, 2014: 2014 Fall Forum of the Antitrust Section of the American Bar Association, (panelist)
"The US Supreme Court: Previewing the October 2014 Term", October 1, 2014: a media briefing hosted by the Washington Legal Foundation, (moderator)
"Antitrust Implications for Cross-licensing", August 8, 2014: at the annual meeting of the American Bar Association, Section of Intellectual Property Law IP Central conference, (presenter)
"A Discussion with the Director of Bureau of Competition of the Federal Trade Commission on the Supreme Court's Actavis Decision", June 12, 2014: at the 2014 Bates White Life Sciences Symposium, (panelist)
"Actavis: One Year Later", June 11, 2014: sponsored by the Intellectual Property and Health Care & Pharmaceuticals Committees of the Antitrust Section of the American Bar Association, (panelist)
"Counseling Pharmaceutical Patent Settlements After Actavis", May 13, 2014: at the Antitrust in Healthcare Conference sponsored by the American Bar Association’s Antitrust and Health Law Sections and the American Health Lawyers Association, (presenter)
"Defense counsel in the mock trial program on 'reverse payment' settlements of pharmaceutical patent litigation under the Supreme Court’s new standard announced in 'FTC v. Actavis'", March 27, 2014: 62nd Annual Antitrust Law Spring Meeting of the American Bar Association
"Liability Risks for Globally Active Companies: Anti-bribery/FCPA and Competition/Antitrust", November 14, 2013: at the Seventh Annual Transatlantic Business Conference sponsored by the American Chamber of Commerce in Germany e.V., (presenter)
"Waking the Sleeping Giant: Competition Issues in the Pharmaceutical Industry", October 3, 2013: at the Annual Competition Law Fall Conference of the Canadian Bar Association, (panelist)
"Working with the DOJ and FTC: How the Agencies Differ at the Investigation Stage", July 30, 2013: sponsored by the Federal Civil Enforcement Committee of the Antitrust Section of the American Bar Association, (panelist)
"Reverse Payments Update: Key Strategies to Bring to the Settlement Table", July 17, 2013: American Conference Institute's Legal and Regulatory Summit on Generic Drugs, (panelist)
"The U.S. Supreme Court: Reviewing the October 2012 Term", June 25, 2013: Washington Legal Foundation, (presenter at the media briefing) (host)
"Reverse Payment Patent Settlements: The Supreme Court Has Spoken", June 18, 2013: sponsored by the Health Care and Pharmaceuticals Committee of the Antitrust Section of the American Bar Association, (panelist)
"Reverse Settlements", June 10, 2013: 2013 Bates White Healthcare & Life Sciences Symposium, (panelist)
"Representing Foreign National Defendants Before the Antitrust Division of DOJ", June 5, 2013: sponsored by the Antitrust Subcommittee of the White Collar Crime Committee of the Criminal Justice Section of the American Bar Association, (panelist)
"Federal Trade Commission v. Actavis, Inc., et al.: Supreme Court Showdown on 'Reverse Payment' Settlements", March 13, 2013: 2013 Patent Litigation Seminar sponsored by the New Jersey Intellectual Property Law Association, (presenter)
"The Dispute Over 'Reverse Payment' Settlements in Pharmaceutical Cases: Will the Supreme Court Have a Cure?", January 24, 2013: Annual Meeting of the Antitrust Law Section of the New York State Bar Association, (panelist)
Lead author of "Recent Antitrust Lessons for the Life Sciences Industry", published by Competition Law360 (October 28, 2019).
Lead author of the "United States: Pharmaceutical Antitrust" chapter in the Global Competition Review's Antitrust Review of the Americas 2016, 2017, 2018, 2019, 2020, 2021, which won the Best Antitrust Business Article – Intellectual Property Category, Concurrences Antitrust Writing Awards in 2018.
Author, "Are Antitrust Violations Crimes Involving Moral Turpitude?," The Champion magazine, published by the National Association of Criminal Defense Lawyers (April 2012 issue), which won a Burton Award for Distinguished Legal Writing in 2013.
"Highly Recommended" for Competition & Antitrust by LMG Life Sciences (2019)
Legal 500: "Recommended" for US Antitrust – Civil Litigation/Class Actions (since 2017)
"Outstanding" Washington, D.C. antitrust practitioner by the Global Competition Review (since 2017)
Best Antitrust Business Article – Intellectual Property Category, Concurrences Antitrust Writing Awards (2018)
Eric Grannon, a partner specializing in antitrust in the Washington, DC office of White & Case LLP, has been named to Who's Who Legal: Competition – Future Leaders 2017, which "aims to profile the foremost practitioners in the competition community (then) aged 45 and under." Incorporating peer acknowledgments, the listing says: "Eric Grannon is 'one of the rising stars of the antitrust bar' who is particularly noted for his 'excellent experience in the pharmaceuticals sector.'"
Named in Euromoney's Guide to the World's Leading Competition and Antitrust Lawyers/Economists (since 2014)
Named one of the Best Lawyers in America for Commercial Litigation (since 2015)
Awarded the 2013 Burton Award for Distinguished Legal Writing for the article, "Are Antitrust Violations Crimes Involving Moral Turpitude?," The Champion magazine, published by the National Association of Criminal Defense Lawyers (April 2012 issue).
Ranked a "Super Lawyer" in the antitrust litigation category by the Washington, D.C. Super Lawyers magazine (since 2013)
Named an antitrust "MVP" for 2012 by Law360, one of eight honorees in the United States. As part of that recognition, the CEO of one client said: "In my position as an executive, it's a very unnerving process to go through depositions while having a business to run.... But Grannon was very collected and focused, and had a very calming approach."
Named a "Litigator of the Week" by the Am Law Litigation Daily for successfully arguing an antitrust appeal against the Federal Trade Commission (FTC) (2012)
Ranked one of the top ten antitrust attorneys in the United States (then) under the age of 40 by Competition Law360 (2010). That ranking observed: "Eric Grannon has a reputation for taking on the U.S. government in high-profile antitrust cases...."